JPH05500155A - Nanbvの診断用薬 - Google Patents
Nanbvの診断用薬Info
- Publication number
- JPH05500155A JPH05500155A JP2508534A JP50853490A JPH05500155A JP H05500155 A JPH05500155 A JP H05500155A JP 2508534 A JP2508534 A JP 2508534A JP 50853490 A JP50853490 A JP 50853490A JP H05500155 A JPH05500155 A JP H05500155A
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- sequence
- clone
- cdna
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title description 2
- 229940079593 drug Drugs 0.000 title description 2
- 239000000523 sample Substances 0.000 claims description 218
- 239000002299 complementary DNA Substances 0.000 claims description 209
- 238000000034 method Methods 0.000 claims description 160
- 239000002773 nucleotide Substances 0.000 claims description 157
- 125000003729 nucleotide group Chemical group 0.000 claims description 156
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 110
- 238000003752 polymerase chain reaction Methods 0.000 claims description 87
- 108091033319 polynucleotide Proteins 0.000 claims description 84
- 102000040430 polynucleotide Human genes 0.000 claims description 84
- 239000002157 polynucleotide Substances 0.000 claims description 84
- 230000000295 complement effect Effects 0.000 claims description 67
- 150000007523 nucleic acids Chemical class 0.000 claims description 60
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 238000009396 hybridization Methods 0.000 claims description 46
- 239000012491 analyte Substances 0.000 claims description 35
- 108091034117 Oligonucleotide Proteins 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 230000008685 targeting Effects 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 13
- 230000000717 retained effect Effects 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000003796 beauty Effects 0.000 claims description 2
- 239000013615 primer Substances 0.000 description 209
- 150000001413 amino acids Chemical class 0.000 description 73
- 239000000047 product Substances 0.000 description 66
- 241000700605 Viruses Species 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 52
- 108020004414 DNA Proteins 0.000 description 48
- 230000003321 amplification Effects 0.000 description 45
- 238000003199 nucleic acid amplification method Methods 0.000 description 45
- 210000002381 plasma Anatomy 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 238000003556 assay Methods 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 30
- 238000002955 isolation Methods 0.000 description 26
- 241000282579 Pan Species 0.000 description 23
- 241000282577 Pan troglodytes Species 0.000 description 23
- 108010076039 Polyproteins Proteins 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 238000001514 detection method Methods 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 19
- 238000012216 screening Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 241000710831 Flavivirus Species 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 16
- 239000002987 primer (paints) Substances 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- 238000011144 upstream manufacturing Methods 0.000 description 15
- 238000012408 PCR amplification Methods 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 229910052698 phosphorus Inorganic materials 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 108091035707 Consensus sequence Proteins 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000012472 biological sample Substances 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 208000006454 hepatitis Diseases 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 206010019799 Hepatitis viral Diseases 0.000 description 8
- 108020000999 Viral RNA Proteins 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 201000001862 viral hepatitis Diseases 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091081021 Sense strand Proteins 0.000 description 7
- 241000710886 West Nile virus Species 0.000 description 7
- 108091036078 conserved sequence Proteins 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 235000019833 protease Nutrition 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241001573186 Citrus keraji Species 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000000211 autoradiogram Methods 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- -1 semi-synthetic Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000001490 Dengue Diseases 0.000 description 5
- 206010012310 Dengue fever Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 208000025729 dengue disease Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 240000005893 Pteridium aquilinum Species 0.000 description 4
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 229910052770 Uranium Inorganic materials 0.000 description 4
- 208000003152 Yellow Fever Diseases 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000010836 blood and blood product Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 238000012317 liver biopsy Methods 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000252233 Cyprinus carpio Species 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241000710781 Flaviviridae Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 241000710772 Yellow fever virus Species 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 229940051021 yellow-fever virus Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 240000000073 Achillea millefolium Species 0.000 description 2
- 235000007754 Achillea millefolium Nutrition 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102100029211 E3 ubiquitin-protein ligase TTC3 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 101000633723 Homo sapiens E3 ubiquitin-protein ligase TTC3 Proteins 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YGLMVCVJLXREAK-MTVMDMGHSA-N 1,1-dimethyl-3-[(1S,2R,6R,7S,8R)-8-tricyclo[5.2.1.02,6]decanyl]urea Chemical compound C([C@H]12)CC[C@@H]1[C@@H]1C[C@@H](NC(=O)N(C)C)[C@H]2C1 YGLMVCVJLXREAK-MTVMDMGHSA-N 0.000 description 1
- UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical class NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101000645498 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_10220 Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241001473877 Biserrula isolate Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101150114104 CROT gene Proteins 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 101001132313 Clostridium pasteurianum 34.2 kDa protein in rubredoxin operon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101000618325 Enterobacteria phage T4 Uncharacterized 12.4 kDa protein in mobB-Gp55 intergenic region Proteins 0.000 description 1
- 101000653284 Enterobacteria phage T4 Uncharacterized 9.4 kDa protein in Gp31-cd intergenic region Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000962067 Gallus gallus Neuroblastoma suppressor of tumorigenicity 1 Proteins 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 235000000434 Melocanna baccifera Nutrition 0.000 description 1
- 241001497770 Melocanna baccifera Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000758676 Pyrococcus woesei Uncharacterized 24.7 kDa protein in gap 5'region Proteins 0.000 description 1
- BERPCVULMUPOER-UHFFFAOYSA-N Quinolinediol Chemical compound C1=CC=C2NC(=O)C(O)=CC2=C1 BERPCVULMUPOER-UHFFFAOYSA-N 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- ODMZDQKUHYGKKN-UHFFFAOYSA-N TCA C Natural products CC(CCCC(C)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3)C(=O)O ODMZDQKUHYGKKN-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010068991 arginyl-threonyl-prolyl-prolyl-prolyl-seryl-glycine Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- VOAXAOULFRTTAM-UHFFFAOYSA-N chloroform phenol Chemical compound C1(=CC=CC=C1)O.C(Cl)(Cl)Cl.C1(=CC=CC=C1)O.C1(=CC=CC=C1)O VOAXAOULFRTTAM-UHFFFAOYSA-N 0.000 description 1
- BKHZIBWEHPHYAI-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol Chemical compound ClC(Cl)Cl.CC(C)CCO BKHZIBWEHPHYAI-UHFFFAOYSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MCQILDHFZKTBOD-UHFFFAOYSA-N diethoxy-hydroxy-imino-$l^{5}-phosphane Chemical compound CCOP(N)(=O)OCC MCQILDHFZKTBOD-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- PZLXYMQOCNYUIO-UHFFFAOYSA-N lithium;hydrochloride Chemical compound [Li].Cl PZLXYMQOCNYUIO-UHFFFAOYSA-N 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.分析物ポリヌクレオチド鎖中のHCV配列にハイプリダイズ可能なオリゴマ ーであって、図18に示すHCVcDNAの、少なくとも4個の連続するヌクレ オチドに相補する、HCVを標的付ける配列を包含する、オリゴマー。 2.前記標的付ける配列が、図18に示す、以下のHCVcDNAヌクレオチド (nnx−nnyはヌクレオチド番号xからヌクレオチド番号yを示す)から選 択されるヌクレオチドに相補する、ヌクレオチドを有する、請求項1に記載のオ リゴマー。 【配列があります】3.前記標的付ける配列が、HCV RNAに保持されるH CVヌクレオチド配列中に存在する、少なくとも8個の配列に相補する配列を有 する、請求項1に記載のオリゴマー。 4.前記保持される配列が、図18における、5′末端から約200までのヌク レオチド番号の配列中に位置する、請求項3に記載のオリゴマー。 5.前記保持される配列が、図18におけるヌクレオチド番号約4000から約 5000に位置する、請求項3に記載のオリゴマー。 6.前記保持される配列が、図18におけるヌクレオチド番号約8000から約 9040に位置する、請求項3に記載のオリゴマー。 7.前記保持される配列が、図18におけるヌクレオチド番号約−318から約 174に位置する、請求項3に記載のオリゴマー。 8.前記保持される配列が、図18におけるヌクレオチド番号約4056から約 4448に位置する、請求項3に記載のオリゴマー。 9.前記保持される配列が、図18におけるヌクレオチド番号約4378から約 4902に位置する、請求項3に記載のオリゴマー。 10.前記保持される配列が、図18におけるヌクレオチド番号約4042から 約4059に位置する、請求項3に記載のオリゴマー。 11.前記保持される配列が、図18におけるヌクレオチド番号約4456から 約4470に位置する、請求項3に記載のオリゴマー。 12.前記保持される配列が、図18におけるヌクレオチド番号約8209から 約8217に位置する、請求項3に記載のオリゴマー。 13.捕捉プローブである、請求項3に記載のオリゴマー。 14.標識プローブである、請求項3に記載のオリゴマー。 15.プライマーである、請求項3に記載のオリゴマー。 16.HCVポリヌクレオチドを含む疑いのある分析物ストランド中のHCV配 列を検出する方法であり、該HCVポリヌクレオチドは選択される標的される部 分を包含し、前記工程は;(a)図18に示す、少なくとも4個の連続するヌク レオチドに相補する、HCVを標的付ける配列を有する、HCVcDNAのヌク レオチド分析物ポリヌクレオチド鎖中のHCV配列にハイプリダイズ可能なオリ ゴマーを提供する工程;(b)分析物ストランドを、標的付ける配列と標的とさ れる配列との間に特異的ハイブリッド2重鎖を形成させる(a)のオリゴマーと インキユベートする工程;および(d)もし存在するならば、標的付ける部分と 該オリゴマーとの間に形成されたハイブリッドを検出する、工程;を包含する、 工程。 17.さらに以下の工程を包含する、請求項16に記載の方法: (a)標的領域に隣接する、ポリメラーゼ連鎖反応のプライマーである一組のオ リゴマーを提供する工程;および(b)ポリメラーゼ連鎖反応により、標的領域 を増幅する工程。 18.分析物中のHCV標的配列を検出するためのキットであって、適当な容器 に包装された請求項1に記載のオリゴマーを含む、キット。 19.HCVを含まない血液を調製するための方法であって、 (a)HCV標的配列を含有すると予想される血液試料から、分析する核酸を提 供する工程; (b)分析するポリヌクレオチド鎖中のHCV配列がもしも存在するならば、そ れにハイプリダイズ可能なオリゴマーを提供する工程であって、該オリゴマーが 、HCVRNAの保持されたHCVヌクレオチド配列中に存在する少なくとも8 個のヌクレオチド配列に相補的な、HCV標的付け配列を含有する、工程; (c)標的付け配列と、もしも存在するなら標的配列との間にポリヌクレオチド 二重鎖を形成可能にする条件下で、(a)に(b)を反応させる工程; (d)もしも存在するなら、(c)中に形成された二重鎖を検出する工程;およ び (e)(d)で二重鎖が検出されなかった血液を蓄える工程、 を包含する、方法。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35596189A | 1989-05-18 | 1989-05-18 | |
US355,961 | 1989-05-18 | ||
US45663789A | 1989-12-21 | 1989-12-21 | |
US456,637 | 1989-12-21 | ||
US50543590A | 1990-04-04 | 1990-04-04 | |
US505,435 | 1990-04-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP30570796A Division JP3701754B2 (ja) | 1989-05-18 | 1996-10-30 | Nanbvの診断法:c型肝炎ウイルスのスクリーニングに有用なポリヌクレオチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05500155A true JPH05500155A (ja) | 1993-01-21 |
JP2656996B2 JP2656996B2 (ja) | 1997-09-24 |
Family
ID=27408242
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2508534A Expired - Lifetime JP2656996B2 (ja) | 1989-05-18 | 1990-05-18 | Nanbvの診断用薬 |
JP30570796A Expired - Lifetime JP3701754B2 (ja) | 1989-05-18 | 1996-10-30 | Nanbvの診断法:c型肝炎ウイルスのスクリーニングに有用なポリヌクレオチド |
JP14598597A Expired - Lifetime JP3698520B2 (ja) | 1989-05-18 | 1997-05-19 | Nanbvの診断法:c型肝炎ウイルスのスクリーニングに有用なポリヌクレオチド |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP30570796A Expired - Lifetime JP3701754B2 (ja) | 1989-05-18 | 1996-10-30 | Nanbvの診断法:c型肝炎ウイルスのスクリーニングに有用なポリヌクレオチド |
JP14598597A Expired - Lifetime JP3698520B2 (ja) | 1989-05-18 | 1997-05-19 | Nanbvの診断法:c型肝炎ウイルスのスクリーニングに有用なポリヌクレオチド |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0398748B1 (ja) |
JP (3) | JP2656996B2 (ja) |
AT (1) | ATE211772T1 (ja) |
AU (1) | AU638719B2 (ja) |
BG (1) | BG60348B2 (ja) |
CA (1) | CA2017157C (ja) |
DE (1) | DE69033891T2 (ja) |
DK (1) | DK0398748T3 (ja) |
ES (1) | ES2166749T3 (ja) |
FI (1) | FI105279B (ja) |
GE (1) | GEP20002164B (ja) |
HU (1) | HUT59964A (ja) |
LV (1) | LV10729B (ja) |
MC (1) | MC2188A1 (ja) |
NO (1) | NO303503B1 (ja) |
RO (1) | RO113059B1 (ja) |
WO (1) | WO1990014436A1 (ja) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6489246A (en) * | 1987-09-30 | 1989-04-03 | Sony Corp | Fixing method for color sorting mechanism of color cathode-ray tube |
US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
AT400724B (de) | 1989-12-18 | 1996-03-25 | Wellcome Found | Virales polypeptid |
CA2044296A1 (en) * | 1990-06-12 | 1991-12-13 | Hiroaki Okamoto | Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus |
US5747339A (en) * | 1990-06-25 | 1998-05-05 | Research Foundation For Microbial Diseases Of Osaka | Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide |
AU7967191A (en) * | 1990-06-30 | 1992-01-23 | Akzo N.V. | Non-a non-b sequences |
DK0469348T3 (da) * | 1990-07-11 | 1997-04-01 | Shionogi & Co | cDNA-sekvens og detektering af hepatitis C-virus |
WO1992001714A1 (en) * | 1990-07-24 | 1992-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Non-a non-b hepatitis virus antigen |
EP0543924B1 (en) * | 1990-08-10 | 1997-06-18 | Chiron Corporation | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
WO1992009634A1 (en) * | 1990-11-29 | 1992-06-11 | Toray Industries, Incorporated | Non-a non-b hepatitis virus antigen protein |
WO1992012992A2 (en) * | 1991-01-14 | 1992-08-06 | James N. Gamble Institute Of Medical Research | Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods |
ES2066547T3 (es) * | 1991-03-01 | 1995-03-01 | Akzo Nobel Nv | Peptidos, inmunoquimicamente reactivos con anticuerpos dirigidos contra virus de hepatitis no-a, no-b. |
US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
EP0510952A1 (en) * | 1991-04-26 | 1992-10-28 | Immuno Japan Inc. | Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus |
FR2677372B1 (fr) * | 1991-06-06 | 1994-11-10 | Pasteur Institut | Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques. |
IT1249684B (it) * | 1991-07-19 | 1995-03-09 | Sorin Biomedica Spa | Epitopi della proteina env del virus dell'epatite c. |
ATE161291T1 (de) * | 1991-08-27 | 1998-01-15 | Hoffmann La Roche | Verfahren und reagenzien zum nachweis von hepatitis c |
WO1993005181A1 (en) * | 1991-09-12 | 1993-03-18 | Cedars-Sinai Medical Center | Direct detection of hepatitis c virus rna |
DE69232859T2 (de) * | 1991-09-13 | 2003-04-10 | Chiron Corp | Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden |
AU3063992A (en) * | 1991-11-07 | 1993-06-07 | Dade International Inc. | Epitope mapping ot the c33c region of hcv |
AU671967B2 (en) * | 1991-11-21 | 1996-09-19 | Common Services Agency | Hepatitis-C virus testing |
GB9204274D0 (en) * | 1992-02-28 | 1992-04-08 | Wellcome Found | Novel peptides |
US5866139A (en) * | 1992-06-04 | 1999-02-02 | Institut Pasteur | Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications |
US5922857A (en) * | 1992-09-28 | 1999-07-13 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
JPH06153961A (ja) * | 1992-11-27 | 1994-06-03 | Imuno Japan:Kk | C型肝炎ウイルス部分遺伝子、ならびにc型肝炎ウイルス遺 伝子の高感度検出法 |
ATE249838T1 (de) | 1993-05-12 | 2003-10-15 | Chiron Corp | Konserviertes motiv der hepatitis c virus e2/ns1 region |
PT773957E (pt) * | 1994-07-29 | 2005-11-30 | Chiron Corp | Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos |
ATE298764T1 (de) | 1994-07-29 | 2005-07-15 | Chiron Corp | Sektretierter e1/e2 hepatitis c virus-komplex erhalten aus c-terminal verkürzten polypeptiden e1 und e2 |
US5837442A (en) | 1995-11-29 | 1998-11-17 | Roche Molecular Systems, Inc. | Oligonucleotide primers for amplifying HCV nucleic acid |
EP0980434B1 (en) | 1997-05-06 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Intracellular production of hepatitis c e2 truncated polypeptid |
DE19832050C2 (de) * | 1998-07-16 | 2002-10-10 | Biotest Pharma Gmbh | Verfahren zum Nachweis von Hepatitis B- bzw. Hepatitis C-Virusgenomen in Plasmaproben und spezifische Primer |
ATE297190T1 (de) | 1999-02-26 | 2005-06-15 | Chiron Corp | Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln |
ES2350306T3 (es) | 1999-02-26 | 2011-01-20 | Novartis Vaccines And Diagnostics, Inc. | Uso de bioadhesivos y adyuvantes para la administración de antígenos por vía mucosa. |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
HU228873B1 (hu) * | 2000-06-15 | 2013-06-28 | Novartis Vaccines & Diagnostic | HCV antigén/ellenanyag kombinációs esszé |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
EP1311289B1 (en) | 2000-08-17 | 2007-10-17 | Tripep Ab | Vaccines containing ribavirin |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
RU2286172C2 (ru) | 2000-08-17 | 2006-10-27 | Трипеп Аб | Вакцины, содержащие рибавирин, и способы их использования |
US6586584B2 (en) | 2001-01-29 | 2003-07-01 | Becton, Dickinson And Company | Sequences and methods for detection of Hepatitis C virus |
ATE472335T1 (de) | 2001-05-31 | 2010-07-15 | Novartis Vaccines & Diagnostic | Chimere alphavirus-replikon-partikel |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
AU2003215316A1 (en) | 2002-02-20 | 2003-09-09 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
US7598421B2 (en) | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
AU2004246999B2 (en) | 2003-02-06 | 2010-06-10 | Aduro Biotech, Inc., | Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
MXPA05008340A (es) | 2003-02-06 | 2006-03-13 | Cerus Corp | Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos. |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20090317420A1 (en) | 2004-07-29 | 2009-12-24 | Chiron Corporation | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
ATE527545T1 (de) | 2004-08-27 | 2011-10-15 | Novartis Vaccines & Diagnostic | Hcv-antigene zur mehrfachen epitopfusion mit modifizierten proteolytischen spaltungsorten und verwendungen davon |
WO2007031867A2 (en) | 2005-05-25 | 2007-03-22 | Tripep Ab | A hepatitis c virus non-stru tural ns3/4a fusion gene |
US20110136678A1 (en) * | 2006-10-20 | 2011-06-09 | Erwin Sablon | Methodology for analysis of sequence variations within the hcv ns3/4a genomic region |
US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
US20090214593A1 (en) | 2007-08-16 | 2009-08-27 | Tripep Ab | Immunogen platform |
US8815253B2 (en) | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
US20110287055A1 (en) | 2008-05-19 | 2011-11-24 | Aduro Biotech | Compositions comprising prfa* mutant listeria and mehtods of use thereof |
WO2010103017A2 (en) | 2009-03-09 | 2010-09-16 | William Henry | Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions |
FI122954B (fi) | 2011-01-31 | 2012-09-14 | Teknoware Oy | LED-putkilamppu ja valaisinjärjestely |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE318216T1 (de) * | 1987-11-18 | 1990-06-13 | Chiron Corp., Emeryville, Calif., Us | Nanbv-diagnostika und vakzine. |
US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
UA50829C2 (uk) * | 1989-03-17 | 2002-11-15 | Чірон Корпорейшн | Очищений поліпептид, що містить антиген вірусу гепатиту с, полінуклеотид, вектор, клітини, система експресії, моноклональне антитіло, препарат поліклональних антитіл, нуклеотидна проба, аналітичні набори, спосіб виявлення нуклеїнових кислот, способи імуноаналізу, вакцина, спосіб одержання антитіл |
CA2032907C (en) * | 1989-12-22 | 2002-05-14 | Richard R. Lesniewski | Hepatitis c assay |
JPH05508762A (ja) * | 1990-04-03 | 1993-12-09 | サウスウエスト・ファウンデイション・フォー・バイオメディカル・リサーチ | 精製されたhcvならびにhcvタンパク質およびペプチド |
-
1990
- 1990-05-18 RO RO149205A patent/RO113059B1/ro unknown
- 1990-05-18 GE GE1876A patent/GEP20002164B/en unknown
- 1990-05-18 MC MC@@@@@@@@@@@@D patent/MC2188A1/xx unknown
- 1990-05-18 WO PCT/US1990/002853 patent/WO1990014436A1/en active IP Right Grant
- 1990-05-18 JP JP2508534A patent/JP2656996B2/ja not_active Expired - Lifetime
- 1990-05-18 EP EP90305421A patent/EP0398748B1/en not_active Expired - Lifetime
- 1990-05-18 AT AT90305421T patent/ATE211772T1/de not_active IP Right Cessation
- 1990-05-18 AU AU58123/90A patent/AU638719B2/en not_active Expired
- 1990-05-18 ES ES90305421T patent/ES2166749T3/es not_active Expired - Lifetime
- 1990-05-18 HU HU904754A patent/HUT59964A/hu unknown
- 1990-05-18 CA CA002017157A patent/CA2017157C/en not_active Expired - Lifetime
- 1990-05-18 DE DE69033891T patent/DE69033891T2/de not_active Expired - Lifetime
- 1990-05-18 DK DK90305421T patent/DK0398748T3/da active
-
1991
- 1991-11-18 BG BG95495A patent/BG60348B2/bg unknown
- 1991-11-18 NO NO914517A patent/NO303503B1/no not_active IP Right Cessation
- 1991-11-18 FI FI915443A patent/FI105279B/fi active
-
1993
- 1993-06-01 LV LVP-93-456A patent/LV10729B/en unknown
-
1996
- 1996-10-30 JP JP30570796A patent/JP3701754B2/ja not_active Expired - Lifetime
-
1997
- 1997-05-19 JP JP14598597A patent/JP3698520B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
LV10729B (en) | 1995-12-20 |
GEP20002164B (en) | 2000-07-10 |
NO303503B1 (no) | 1998-07-20 |
JPH10113176A (ja) | 1998-05-06 |
DK0398748T3 (da) | 2002-03-18 |
WO1990014436A1 (en) | 1990-11-29 |
BG60348B2 (bg) | 1994-06-30 |
EP0398748B1 (en) | 2002-01-09 |
JP3698520B2 (ja) | 2005-09-21 |
JPH1089A (ja) | 1998-01-06 |
MC2188A1 (fr) | 1992-09-16 |
DE69033891T2 (de) | 2002-08-29 |
EP0398748A2 (en) | 1990-11-22 |
FI915443A0 (fi) | 1991-11-18 |
HUT59964A (en) | 1992-07-28 |
AU638719B2 (en) | 1993-07-08 |
LV10729A (lv) | 1995-06-20 |
DE69033891D1 (de) | 2002-02-21 |
JP2656996B2 (ja) | 1997-09-24 |
RO113059B1 (ro) | 1998-03-30 |
JP3701754B2 (ja) | 2005-10-05 |
ATE211772T1 (de) | 2002-01-15 |
HU904754D0 (en) | 1992-01-28 |
EP0398748A3 (en) | 1991-10-23 |
CA2017157C (en) | 2003-07-29 |
FI105279B (fi) | 2000-07-14 |
NO914517D0 (no) | 1991-11-18 |
ES2166749T3 (es) | 2002-05-01 |
AU5812390A (en) | 1990-12-18 |
CA2017157A1 (en) | 1990-11-18 |
NO914517L (no) | 1992-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05500155A (ja) | Nanbvの診断用薬 | |
JP4251407B2 (ja) | Hcv単離物のタイピング法 | |
US5863719A (en) | Methods for detecting hepatitis C virus using polynucleotides specific for same | |
US5714596A (en) | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus | |
KR0163964B1 (ko) | 엔에이엔비브이 진단법: c형 간염바이러스의 스크리닝에 유용한 폴리뉴클레오티드 | |
RU2145635C1 (ru) | Олигомер (варианты), способ обнаружения последовательности hcv (варианты), набор для обнаружения, способ получения крови | |
JPH07501712A (ja) | 微量rnaまはたrnaおよびdna検出用の一段rnaおよび結合一段rnaおよびdnaポリメラーゼ・チェイン・リアクション | |
US8101351B2 (en) | Process for typing of HCV isolates | |
MURPHY et al. | Sequence Analysis of the 5". Noncoding Region Reveals the Existence of Multiple Hepatitis C Virus Genotypes in | |
PT94081B (pt) | Diagnosticos para o nambv: polinucleotidos uteis na deteccao do virus da hepatite c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090530 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090530 Year of fee payment: 12 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090530 Year of fee payment: 12 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100530 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term |